Actively Recruiting
Phase 1 Study of GSK4771261 Given as a Single Subcutaneous Dose to Healthy Adults Aged 25 to 55 of Chinese, Japanese, or WhiteEuropean Ancestry to Assess Safety and Immune Response
Led by GlaxoSmithKline · Updated on 2026-10-05
30
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating GSK4771261, a medication given as a single subcutaneous dose, in healthy adults aged 25 to 55 years from Chinese, Japanese, and WhiteEuropean ancestry. This phase 1 study aims to assess the safety, tolerability, how the drug is processed by the body, and whether it triggers an immune response. Participants will be randomly assigned to receive either GSK4771261 or a placebo. The study uses a double-blind design, meaning neither participants nor researchers know who receives the drug or placebo. The treatment is administered once, and participants are monitored closely throughout the study. During participation, individuals will undergo medical evaluations, laboratory tests, vital sign checks, and heart monitoring via ECG up to 13 weeks after dosing. Researchers will track any side effects, immune responses, and drug levels in the blood. The total study duration includes screening, treatment, and follow-up assessments to ensure safety and collect detailed information on the drugs effects.
CONDITIONS
Brief Title
A Study of GSK4771261 in Healthy Participants Aged 25 to 55 Years of Age Inclusive
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here